Novo Nordisk's CEO said that the 2035 pipeline product sales target has been factored into the risk adjustment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.